https://novaprd-lb.newcastle.edu.au/vital/access/manager/Index en-au 5 Patient-determined disease steps is not interchangeable with the Expanded Disease Status Scale in mild to moderate multiple sclerosis https://novaprd-lb.newcastle.edu.au/vital/access/manager/Repository/uon:54397 Wed 21 Feb 2024 15:48:45 AEDT ]]> Switching to natalizumab or fingolimod in multiple sclerosis: Comparative effectiveness and effect of pre-switch disease activity https://novaprd-lb.newcastle.edu.au/vital/access/manager/Repository/uon:51306 Thu 31 Aug 2023 14:27:51 AEST ]]> Comparison Between Dimethyl Fumarate, Fingolimod, and Ocrelizumab After Natalizumab Cessation https://novaprd-lb.newcastle.edu.au/vital/access/manager/Repository/uon:52624 Thu 19 Oct 2023 14:15:33 AEDT ]]> Association between cognitive trajectories and disability progression in patients with relapsing-remitting multiple sclerosis https://novaprd-lb.newcastle.edu.au/vital/access/manager/Repository/uon:46218 Mon 14 Nov 2022 12:12:01 AEDT ]]> Comparing switch to ocrelizumab, cladribine or natalizumab after fingolimod treatment cessation in multiple sclerosis https://novaprd-lb.newcastle.edu.au/vital/access/manager/Repository/uon:53317 Fri 19 Jan 2024 14:25:45 AEDT ]]>